Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD19 inhibitor

DRUG CLASS:

CD19 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
CD20 positive	B Acute Lymphoblastic Leukemia	CD20 positive	B Acute Lymphoblastic Leukemia	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2